Acknowledgment Of Luekemia

This study was supported in part by the Lymphoma Foundation and Victoria's Smile Foundation.

14. Ishii E, Mara T, Ohkubo K, et al.: Treatment of childhood acute lymphoblastic leukemia with intermediate-dose cytosine arabinoside and adriamycin. Med Pediatr Oncol 14:73, 1986.

15. Kantarjian HM, Estey EH, Plunkett W, et al.: Phase I-II clinical and pharmacologic studies of high-dose cyto-sine arabinoside in refractory leukemia. Am J Med 81:387, 1986.

16. Capizzi RI, Poole M, Cooper MR, et al.: Treatment of poor risk acute leukemia with sequential high-dose Ara-C and asparaginase. Blood 63:694, 1984.

17. Amadori S, Papa F, Avvisati G, et al.: Sequential combination high-dose Ara-C and asparaginase for the treatment of advanced acute leukemia and lymphoma. Leuk Res 8:729, 1984.

18. Wells RJ, Feusner J, Devney R, et al.: Sequential highdose cytosine arabinoside-asparaginase treatment in advance childhood leukemia. J Clin Oncol 3:998, 1985.

19. Ishii E, Mara T, Ohkubo K, et al.: Treatment of childhood acute lymphoblastic leukemia with intermediate-dose cytosine arabinoside and adriamycin. Med Pediatr Oncol 14:73, 1986.

20. Giona F, Testi A, Amadori G, et al.: Idarubicin and highdose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia. Ann Oncol 1:51, 1990.

21. Tan C, Steinherz P, Meyer P: Idarubicin in combination with high-dose cytosine arabinoside in patients with acute leukemia in relapse [abstract]. Proc Annu Meet Am Assoc Cancer Res 31:A1133, 1990.

22. Camera A, Annino L, Chiurazzi F, et al.: GIMEMA ALL -Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia. Haematologica 89:145-153, 2004.

23. Hiddemann W, Kreutzman H, Straif K, et al.: High-dose cytosine arabinoside in combination with mitox-antrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Semin Oncol 14:73, 1987.

24. Leclerc J, Rivard G, Blanch M, et al.: The association of once a day high-dose Ara-C followed by mitoxantrone for three days induces a high rate of complete remission in children with poor prognosis acute leukemia [abstract]. Blood 72(suppl):210, 1988.

25. Kantarjian H, Walters R, Keating M, et al.: Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer 65:5, 1990.

26. Feldman EJ, Alberts DS, Arlin Z, et al.: Phase I clinical and pharmacokinetic evaluation of high-dose mitox-antrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 11:2002, 1993.

27. Weiss MA, Drullinsky P, Maslak P, et al.: A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Leukemia 12(6):865-868, 1998.

28. Weiss MA, Aliff TB, Tallman MS, et al.: A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer 95(3):581-587, 2002.

29. Davies SM, Ramsay NK, Weisdorf DJ: Feasibility and timing of unrelated donor identification for patients with ALL. Bone Marrow Transplant 17:737-740, 1996.

30. Gale RP, Horowitz MM, Ash RC, et al.: Identical-twin bone marrow transplants for leukemia. Ann Intern Med 120:646, 1994.

31. Kolb H-J, Scattenberg A, Goldman JM, et al.: Graft-ver-sus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041, 1995.

32. Doney K, Fisher LD, Appelbaum FR, et al.: Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant 7:453, 1991.

33. Annaloro C, Curioni ACE, Molteni M, et al.: Hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: a single-centre analysis. Leuk Lymph 45:1175, 2004.

34.Sebban C, Lepage E, Vernant J-P, et al.: Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in first complete remission: a comparative study. J Clin Oncol 12:2580, 1994.

35. Zhang M-J, Hoelzer D, Horowitz MM, et al.: Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. Ann Intern Med 123:428, 1995.

36. Attal M, Blaise D, Marit G, et al.: Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autolo-gous bone marrow transplant. Blood 86:1619, 1995.

37. Capizzi RL, Keeser LW, Sartorelli AC: Combination chemotherapy: theory and practice. Semin Oncol 4:227, 1977.

38. Beatty PG, Hansen JA, Longton GM, et al.: Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 51:443, 1991.

39. Gunther R, Chelstrom LM, Finnegan D, et al.: In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency. Leukemia 7:298, 1993.

40.Mehta J, Powles R, Treleaven J, et al.: Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia: Long-term follow-up. LeukLymphoma 25:479, 1997.

41.Maldonado MS, Diaz-Heredia C, Badell I, et al.: Autologous bone marrow transplantation with monoclonal antibody purged marrow for children with acute lymphoblastic leukemia in second remission--Spanish

Working Party for BMT in Children. Bone Marrow Transplant 22:1043, 1998.

42.Thiebaut A, Vernant JP, Degos L, et al.: Adult acute lym-phocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87 (Review). Hematol Oncol Clin N Amer 14:1353-1366, 2000.

43. Fiere D, Lepage E, Sebban C, et al.: Adult acute lym-phoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. J Clin Oncol 11:1990, 1993.

44. Barrett AJ, Horowitz, MM, Ash RC, et al.: Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 79:3067-3070, 1992.

45.Dombret H, Gabert J, Boiron JM, et al.: Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 trial. Blood 100:23572366, 2002.

46. Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001.

47. Ottmann OG, Druker BJ, Sawyers CL, et al.: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100:1965-1971, 2002.

48. Hoffman WK, Jones JC, Lemp NA, et al.: Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99:1860-1862, 2002.

49. Hoffman WK, Komor M, Wassman B, et al.: Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (ima-tinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 102:659-661, 2003.

50. Wassman B, Pfeifer H, Scheuring UJ, et al.: Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treated with imatinib. Blood 103: 1495-1498, 2004.

51. Thomas DA, Faderl S, Cortes J, et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103(12):4396-4407, 2004.

52. Wassmann B, Scheuring U, Pfeifer H, et al.: Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Leukemia 17:1919-1924, 2003.

53. Sanders KE, Ha CS, Cortes-Franco JE, et al.: The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia. Cancer 100:216-2180, 2004.

54a. Kantarjian H, Gandhi V, Cortes J, et al.: Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102:2379, 2003.

54b.Jeha S, Gaynon PS, Razzouk BI, et al.: Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 24(12):1917, 2006.

55. Gandhi V, Plunkett W, Rodriguez CO Jr, et al.: Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol 16: 3607-3615, 1998.

56. Gandhi V, Plunkett W, Weller S, et al.: Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol 19(8):2142-2152, 2001.

57. Rodriguez CO Jr, Stellrecht CM, Gandhi V: Mechanisms of T-cell selective cytotoxicity of arabinosylguanine. Blood 102(5):1842-1848, 2003.

58. Keating MJ, Byrd J, Rai K, et al.: Campath-1H Collaborative Study Group: Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia (B-CLL) refractory to fludarabine [abstract]. Blood 94(suppl 1):705a, 1999. Abstract 3118.

59. Osterborg A, Dyer MJ, Bunjes D, et al.: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia, European Study Group of Campath-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15:1567, 1997.

60. Rai KR, Freter CE, Mercier RJ, et al.: Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20:3891-3897, 2002.

61. Dyer MJS, Hale G, Hayhoe FGJ, et al.: Effects of Campath-IH antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73:1431, 1989.

62. Mehta J, Powles R, Treleaven J, et al.: Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia: long-term follow-up. Leuk Lymphoma 25:479-486, 1997.

63. Piccaluga PP, Martineli G, Malagola M, et al.: Antileukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. Leuk Lymphoma 45:731-733, 2004.

64. Novitzy N, Thomas V, Hale G, Waldmann H: Ex vivo depletion of T cells from bone marrow grafts with Campath-1H in acute leukemia: graft-versus-host disease and graft-versus-leukemia effect. Transplantation 67:620-626, 1999.

This page intentionally left blank

Section

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment